GoAI
Get started
SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$3.04

+$0.07 · +2.36%

Aug 21, 4:00 PM ET

SIGA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

82

Deep Value

Momentum

21

Weakening

Sentiment

72

Bullish

Risk resilience

39

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Diem Nguyen
Listed since
Sep 10, 1997
Employees
49

Market position

Day range

Current $3.04

52-week range

Current $3.04

Open
$2.99
Previous close
$2.97
Volume
1.54M
2.51× average
Average volume
613.09K
Average daily volume
Market cap
218.04M USD
Beta
0.89
Market reference 1
50-day average
$3.5114
-13.42% below average
200-day average
$5.1632
-41.12% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
283.14M USD
P/E (TTM)
-69.72×
P/B (TTM)
1.32×
P/S (TTM)
4.06×
EV / EBITDA
9.14×
Earnings yield
5.33%
Free cash flow yield
9.86%
Dividend yield
19.74%

Profitability & efficiency

Gross margin
54.35%
Operating margin
-20.76%
Net margin
-5.14%
Return on equity
11.72%
Return on assets
10.62%
Return on invested capital
8.99%

Financial health

Debt / equity
0×
Current ratio
11.83×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends97%71%44%18%Gross margin, FY2021: 87.58%Gross margin, FY2022: 90.58%Gross margin, FY2023: 87.26%Gross margin, FY2024: 77.44%Gross margin, FY2025: 68.57%Operating margin, FY2021: 66.65%Operating margin, FY2022: 38.55%Operating margin, FY2023: 59.76%Operating margin, FY2024: 50.45%Operating margin, FY2025: 25.05%Net margin, FY2021: 51.96%Net margin, FY2022: 30.61%Net margin, FY2023: 48.65%Net margin, FY2024: 42.69%Net margin, FY2025: 24.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 87.58%. Gross margin FY2022 90.58%. Gross margin FY2023 87.26%. Gross margin FY2024 77.44%. Gross margin FY2025 68.57%. Operating margin FY2021 66.65%. Operating margin FY2022 38.55%. Operating margin FY2023 59.76%. Operating margin FY2024 50.45%. Operating margin FY2025 25.05%. Net margin FY2021 51.96%. Net margin FY2022 30.61%. Net margin FY2023 48.65%. Net margin FY2024 42.69%. Net margin FY2025 24.63%.

Income trends

Revenue

94.6M USD-31.80%

Operating income

23.7M USD-66.13%

Net income

23.3M USD-60.65%
Income trends across reported periods151.58M USD104.93M USD58.29M USD11.64M USDRevenue, FY2021: 133.67M USDRevenue, FY2022: 110.78M USDRevenue, FY2023: 139.92M USDRevenue, FY2024: 138.72M USDRevenue, FY2025: 94.6M USDOperating income, FY2021: 89.09M USDOperating income, FY2022: 42.7M USDOperating income, FY2023: 83.62M USDOperating income, FY2024: 69.98M USDOperating income, FY2025: 23.7M USDNet income, FY2021: 69.45M USDNet income, FY2022: 33.9M USDNet income, FY2023: 68.07M USDNet income, FY2024: 59.21M USDNet income, FY2025: 23.3M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 133.67M USD. Revenue FY2022 110.78M USD. Revenue FY2023 139.92M USD. Revenue FY2024 138.72M USD. Revenue FY2025 94.6M USD. Operating income FY2021 89.09M USD. Operating income FY2022 42.7M USD. Operating income FY2023 83.62M USD. Operating income FY2024 69.98M USD. Operating income FY2025 23.7M USD. Net income FY2021 69.45M USD. Net income FY2022 33.9M USD. Net income FY2023 68.07M USD. Net income FY2024 59.21M USD. Net income FY2025 23.3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue94.6M USD138.72M USD139.92M USD110.78M USD133.67M USD
Cost of goods sold29.7M USD31.29M USD17.83M USD10.43M USD16.6M USD
Gross profit64.87M USD107.43M USD122.09M USD100.34M USD117.07M USD
Research and development6.53M USD12.31M USD16.43M USD22.53M USD9.94M USD
Selling, general, and administrative3.13M USD25.14M USD22.04M USD35.12M USD18.03M USD
Operating expenses41.17M USD37.45M USD38.47M USD57.64M USD27.98M USD
Interest income6.68M USD————
Depreciation and amortization562.61K USD538.42K USD538.29K USD517.64K USD522.37K USD
Operating income23.7M USD69.98M USD83.62M USD42.7M USD89.09M USD
Net income23.3M USD59.21M USD68.07M USD33.9M USD69.45M USD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.17

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.690.410.13-0.15Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 7, 2024: actual 0.02, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 11, 2025: actual 0.63, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual -0.01, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual 0.49, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual -0.09, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 10, 2026: actual -0.08, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 7, 2026: actual -0.05, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 0.17, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates87.78M59.26M30.74M2.23MQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 7, 2024: actual 10.01M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 11, 2025: actual 81.47M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 7.04M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 5, 2025: actual 81.12M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual 2.62M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 10, 2026: actual 3.8M USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 7, 2026: actual 6.24M USD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 41M USD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.60

2025 complete year+33.3% since 2022

2026 partial: $0.60

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Apr 7, 2026

$0.60

Special

Record Apr 7, 2026 · Payment Apr 23, 2026

Dividend

Ex-dividend Apr 29, 2025

$0.60

Special

Record Apr 29, 2025 · Payment May 15, 2025

Dividend

Ex-dividend Mar 25, 2024

$0.60

Special

Record Mar 26, 2024 · Payment Apr 11, 2024

Dividend

Ex-dividend May 15, 2023

$0.45

Special

Record May 16, 2023 · Payment Jun 1, 2023

Dividend

Ex-dividend May 16, 2022

$0.45

Special

Record May 17, 2022 · Payment Jun 2, 2022

SIGA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SIGA

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
4.2M
Weight
0.01%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.94M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.31M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.61M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.16M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Fidelity Small-Mid Multifactor ETF logoFidelity Small-Mid Multifactor ETFFSMD
Market value
1.1M
Weight
0.03%
AUM
2.5B USD
Expense ratio
0.15%
Price / 1D
$52.03+0.44%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
782.04K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
759.87K
Weight
0.01%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research SIGA

research.disclaimer